Caelyx (Liposomal Doxorubicin) and Carboplatin Treatment Regimen
Reading tools
In this article
Epithelial ovarian cancer is usually diagnosed at an advanced stage and carries a high risk of recurrence. Platinum-based combinations are the foundation of treatment. In this context, Caelyx (PLD) + carboplatinis among the regimens that offer a good balance of efficacy and tolerability, particularly in platinum-sensitive recurrence.
With longer progression-free survival (PFS) and a lower neurotoxicity profile, it is a strong alternative to the conventional paclitaxel–carboplatin regimen.
1) What Are Carboplatin and Caelyx?
- Caelyx (Pegylated Liposomal Doxorubicin, PLD): A formulation of the anthracycline doxorubicin encapsulated in PEG-coated stealth liposomes, designed for prolonged circulation and selective accumulation in tumors.
- Carboplatin: A platinum-based chemotherapeutic agent that forms intrastrand/interstrand DNA crosslinks and is dosed according to renal function using the Calvert formula .
2) How Does It Work?
PLD (Caelyx):
- DNA intercalation + topoisomerase II inhibition
- Liposomal/PEG-coated structure → prolonged circulation and tumor accumulation through the EPR effect
- Compared with conventional doxorubicin, cardiotoxicity is lower (cumulative risk must still be monitored)
Carboplatin:
- DNA crosslinks → inhibition of replication/transcription
- Nephrotoxicity and peripheral neuropathy are milder than with cisplatin
- Dose: target AUC × (GFR + 25) — Calvert
3) Goals of This Treatment
- Reduce tumor burden and symptoms; prolong PFSduration
- Minimize side effects that affect quality of life, such as hair loss and neuropathy
- Achieve effective cytoreduction before maintenance/subsequent-line biological approaches (e.g., PARP inhibitors)
4) Approved Indication and Clinical Role
PLD (Caelyx/Doxil) is approved for ovarian cancer; its combination with carboplatin is one of the standard options for platinum-sensitive recurrence. International guidelines (ESMO, etc.) recommend carboplatin combinations with paclitaxel, gemcitabine or PLD in platinum-sensitive relapse.
5) Summary of the Evidence (CALYPSO and Others)
- CALYPSO Phase III (CD vs CP): Carboplatin+PLD (CD) vs carboplatin+paclitaxel (CP). PFS was superior in the CD arm; less alopecia and neuropathy. OS was similar; the therapeutic index favored CD.
- Subgroup analyses: The PFS benefit of CD is maintained in “very platinum-sensitive” cases as well.
- Guidelines: CD is an effective and well-tolerated option for patients with platinum-sensitive recurrence.
6) Dosing and Administration Schedule
| Drug | Recommended Dose | Administration | Cycle |
|---|---|---|---|
| Caelyx® (PLD) | 50 mg/m² (labeled ovarian cancer dose) Common alternative in combination: 30–40 mg/m² |
IV infusion ≥60 min (a slower initial rate may be used in the first cycle) | Day 1, every 28 days × 6 cycles (tolerance/response) |
| Carboplatin | AUC 4–5 (Calvert: Total dose = AUC × (GFR + 25)) | IV over 30–60 min (premedication according to emetic risk) | Day 1, every 28 days × 6 cycles |
Note: The PLD label specifies 50 mg/m²/28 days for ovarian cancer; reducing the combination dose to 30–40 mg/m² to lower the risk of hand–foot syndrome/mucositis is common practice; follow your center’s protocol.
Both drugs are reimbursed by SGK.
7) Practical Considerations
- Infusion reaction (PLD): Flushing, dyspnea and back pain may occur in the early minutes; stop/slow the infusion and give an antihistamine ± steroid. Use a slower rate in the first cycle.
- Cumulative anthracycline dose: Monitor cardiac function in patients with prior anthracycline exposure; bear in mind equivalent cumulative limits of 450–550 mg/m² (even though the risk is lower with PLD).
- Emesis prophylaxis: Carboplatin AUC ≥4 is moderately emetogenic; 5-HT3 ± dexamethasone.
- Hand–foot syndrome / mucositis: Moisturizer, cooling, avoidance of friction and oral hygiene; interrupt/reduce the dose at early signs.
- Hematological toxicity: Delay the cycle/reduce the dose according to ANC/PLT thresholds; G-CSF for febrile neutropenia.
8) Pretreatment Assessments and Monitoring Between Visits
- Baseline: Complete blood count, biochemistry (creatinine, eGFR, AST/ALT/bilirubin), ECG, if needed, echocardiography (LVEF), performance status, peripheral neuropathy, oral/dental and dermatological assessment.
- Before each cycle: CBC; if neutrophils are not ≥1.5×109/L and PLT not ≥100×109/L, delay treatment; recalculate the carboplatin dose using renal function; grade hand–foot syndrome and stomatitis.
- Between cycles: Fever/infection symptoms, mucositis, dermatological findings, nephrotoxicity/ototoxicity/neuropathy; assess LVEF if cardiac symptoms occur.
9) Patient Selection Criteria
- Platinum-sensitive recurrence: Relapse ≥6 months after the last platinum treatment
- Adequate organ function (bone marrow, kidney, liver), ECOG 0–2
- In patients with significant peripheral neuropathy, it offers an advantage as an alternative to paclitaxel
- With prior high cumulative anthracycline exposure/cardiac risk, it may be used with careful cardiac monitoring
10) Drug Interactions
- PLD (anthracycline): Cardiac risk with other cardiotoxic agents (e.g., trastuzumab, high-dose cyclophosphamide); infection risk with strong immunosuppressants; myelosuppressive drugs increase hematological toxicity.
- Carboplatin: Increased toxicity with nephrotoxic/ototoxic drugs; live vaccines are contraindicated; fluctuations in antiepileptic levels (e.g., phenytoin).
11) Side Effects and Management
| Side Effect | Frequency (all grades / ≥3) | Management |
|---|---|---|
| Neutropenia | ~35–45% / 10–20% | Delay the cycle, reduce the dose; G-CSF for FN |
| Thrombocytopenia | ~20–30% / 5–10% | Delay the cycle; transfusion if needed |
| Stomatitis/Mucositis (PLD) | ~20–40% / 5–10% | Oral hygiene, topical agents; interrupt/reduce the dose at ≥G2 |
| Hand–foot syndrome (PPE) | ~20–40% / 5–10% | Moisturizer/cooling; close monitoring; restart at a reduced dose at G≤1 |
| Allergic/Infusion reaction | ~5–15% / <5% | Stop/slow the infusion; antihistamine ± steroid |
| Peripheral neuropathy (less than with CP) | ~10–15% / <5% | Dose modification; rehabilitation ± B6 |
| Cardiac dysfunction (rare) | <2% / <1% | Echocardiography for symptoms; review cumulative dose |
Percentages may vary by study/schedule; PPE and stomatitis are generally less frequent with the combination than with PLD monotherapy.
12) Dose Modifications
- Hematology: If ANC is <1.5×109/L or PLT <100×109/L, delay the cycle by 1 week; if recurrent, reduce PLD by 25% and carboplatin by AUC-0.5.
- Stomatitis/Hand–foot syndrome (≥G2): Interrupt until recovery; reduce PLD by one dose level when restarting (e.g., 50→40→30 mg/m²). Consider discontinuation for persistent ≥G3.
- Renal function: Before each cycle, the carboplatin dose is calculated using the current GFR again ; the target AUC remains unchanged.
- Cardiac event/symptom: Stop PLD; decide based on cardiology assessment and LVEF.
13) References
- Pujade-Lauraine E, et al. CALYPSO: Carboplatin-PLD vs Carboplatin-Paclitaxel in platinum-sensitive ROC. J Clin Oncol. 2010;28:3323-3329.
- Final OS results of CALYPSO (GCIG). Br J Cancer. 2012;107:588-591.
- DOXIL® (doxorubicin HCl liposome) US Prescribing Information, latest update.
- Caelyx® (PLD) EMA Product Information (SmPC), current version.
- ESMO Clinical Practice Guideline: Newly diagnosed and relapsed epithelial ovarian cancer (2023).
- Calvert AH, et al. JCO 1989;7:1748-1756 (Calvert formula).
- BC Cancer Drug Monograph: Carboplatin (current).
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.